Safety issues and concerns of new immunomodulators in rheumatology

Carlo Selmi, Angela Ceribelli, Stanley M Naguwa, Luca Cantarini, Yehuda Shoenfeld

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Introduction: The development of biologic therapies has been an enormous leap in the management of patients with rheumatoid and psoriatic arthritis. Since the first anti-TNF-α therapies, numerous molecules have been identified as targets of immunomodulatory therapies, such as IL-1 (anakinra, canakinumab), IL-6 (tocilizumab), CD20+ B cells (rituximab), CTLA4 (abatacept) and two additional anti-TNF-α therapies (certolizumab pegol, golimumab).Areas covered: In the present review, we will describe the safety issues related to the immunosuppressive action of these biologic drugs that are mainly represented by infection and malignancy. The risk of infection should be identified before initiating a biologic treatment and markers checked over time, in particular for tuberculosis and hepatitis B and C viruses. Other infections (bacterial, viral, parasitic; opportunistic; surgery-related) and safety issues may require temporary interruption of the treatment until complete resolution. No significantly increased risk of malignancy, both hematological and solid, has been associated with the use of biologic agents. In all cases, it is difficult to dissect the risks related to biologics from those related to baseline treatments.Expert opinion: Detailed medical history and laboratory screening should be performed before starting biologic therapies. Clinicians should be aware of the different safety profiles associated with different molecules and they should follow up data coming out of the existing registries for biologics in regard to new or old side effects.

Original languageEnglish (US)
Pages (from-to)389-399
Number of pages11
JournalExpert Opinion on Drug Safety
Volume14
Issue number3
DOIs
StatePublished - Mar 1 2015

Fingerprint

Immunologic Factors
Rheumatology
Safety
Biological Therapy
Biological Products
Interleukin 1 Receptor Antagonist Protein
Therapeutics
Psoriatic Arthritis
Immunomodulation
Expert Testimony
Biological Factors
Virus Diseases
Hematologic Neoplasms
Immunosuppressive Agents
Infection
Interleukin-1
Bacterial Infections
Hepatitis B virus
Hepacivirus
Registries

Keywords

  • Adverse event
  • Biologic registry
  • Cancer
  • Infection
  • TNF-α inhibitor

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Safety issues and concerns of new immunomodulators in rheumatology. / Selmi, Carlo; Ceribelli, Angela; Naguwa, Stanley M; Cantarini, Luca; Shoenfeld, Yehuda.

In: Expert Opinion on Drug Safety, Vol. 14, No. 3, 01.03.2015, p. 389-399.

Research output: Contribution to journalArticle

Selmi, Carlo ; Ceribelli, Angela ; Naguwa, Stanley M ; Cantarini, Luca ; Shoenfeld, Yehuda. / Safety issues and concerns of new immunomodulators in rheumatology. In: Expert Opinion on Drug Safety. 2015 ; Vol. 14, No. 3. pp. 389-399.
@article{e94de61b754c428eb841e035bb065304,
title = "Safety issues and concerns of new immunomodulators in rheumatology",
abstract = "Introduction: The development of biologic therapies has been an enormous leap in the management of patients with rheumatoid and psoriatic arthritis. Since the first anti-TNF-α therapies, numerous molecules have been identified as targets of immunomodulatory therapies, such as IL-1 (anakinra, canakinumab), IL-6 (tocilizumab), CD20+ B cells (rituximab), CTLA4 (abatacept) and two additional anti-TNF-α therapies (certolizumab pegol, golimumab).Areas covered: In the present review, we will describe the safety issues related to the immunosuppressive action of these biologic drugs that are mainly represented by infection and malignancy. The risk of infection should be identified before initiating a biologic treatment and markers checked over time, in particular for tuberculosis and hepatitis B and C viruses. Other infections (bacterial, viral, parasitic; opportunistic; surgery-related) and safety issues may require temporary interruption of the treatment until complete resolution. No significantly increased risk of malignancy, both hematological and solid, has been associated with the use of biologic agents. In all cases, it is difficult to dissect the risks related to biologics from those related to baseline treatments.Expert opinion: Detailed medical history and laboratory screening should be performed before starting biologic therapies. Clinicians should be aware of the different safety profiles associated with different molecules and they should follow up data coming out of the existing registries for biologics in regard to new or old side effects.",
keywords = "Adverse event, Biologic registry, Cancer, Infection, TNF-α inhibitor",
author = "Carlo Selmi and Angela Ceribelli and Naguwa, {Stanley M} and Luca Cantarini and Yehuda Shoenfeld",
year = "2015",
month = "3",
day = "1",
doi = "10.1517/14740338.2015.993605",
language = "English (US)",
volume = "14",
pages = "389--399",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Safety issues and concerns of new immunomodulators in rheumatology

AU - Selmi, Carlo

AU - Ceribelli, Angela

AU - Naguwa, Stanley M

AU - Cantarini, Luca

AU - Shoenfeld, Yehuda

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Introduction: The development of biologic therapies has been an enormous leap in the management of patients with rheumatoid and psoriatic arthritis. Since the first anti-TNF-α therapies, numerous molecules have been identified as targets of immunomodulatory therapies, such as IL-1 (anakinra, canakinumab), IL-6 (tocilizumab), CD20+ B cells (rituximab), CTLA4 (abatacept) and two additional anti-TNF-α therapies (certolizumab pegol, golimumab).Areas covered: In the present review, we will describe the safety issues related to the immunosuppressive action of these biologic drugs that are mainly represented by infection and malignancy. The risk of infection should be identified before initiating a biologic treatment and markers checked over time, in particular for tuberculosis and hepatitis B and C viruses. Other infections (bacterial, viral, parasitic; opportunistic; surgery-related) and safety issues may require temporary interruption of the treatment until complete resolution. No significantly increased risk of malignancy, both hematological and solid, has been associated with the use of biologic agents. In all cases, it is difficult to dissect the risks related to biologics from those related to baseline treatments.Expert opinion: Detailed medical history and laboratory screening should be performed before starting biologic therapies. Clinicians should be aware of the different safety profiles associated with different molecules and they should follow up data coming out of the existing registries for biologics in regard to new or old side effects.

AB - Introduction: The development of biologic therapies has been an enormous leap in the management of patients with rheumatoid and psoriatic arthritis. Since the first anti-TNF-α therapies, numerous molecules have been identified as targets of immunomodulatory therapies, such as IL-1 (anakinra, canakinumab), IL-6 (tocilizumab), CD20+ B cells (rituximab), CTLA4 (abatacept) and two additional anti-TNF-α therapies (certolizumab pegol, golimumab).Areas covered: In the present review, we will describe the safety issues related to the immunosuppressive action of these biologic drugs that are mainly represented by infection and malignancy. The risk of infection should be identified before initiating a biologic treatment and markers checked over time, in particular for tuberculosis and hepatitis B and C viruses. Other infections (bacterial, viral, parasitic; opportunistic; surgery-related) and safety issues may require temporary interruption of the treatment until complete resolution. No significantly increased risk of malignancy, both hematological and solid, has been associated with the use of biologic agents. In all cases, it is difficult to dissect the risks related to biologics from those related to baseline treatments.Expert opinion: Detailed medical history and laboratory screening should be performed before starting biologic therapies. Clinicians should be aware of the different safety profiles associated with different molecules and they should follow up data coming out of the existing registries for biologics in regard to new or old side effects.

KW - Adverse event

KW - Biologic registry

KW - Cancer

KW - Infection

KW - TNF-α inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84923319847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923319847&partnerID=8YFLogxK

U2 - 10.1517/14740338.2015.993605

DO - 10.1517/14740338.2015.993605

M3 - Article

C2 - 25518908

AN - SCOPUS:84923319847

VL - 14

SP - 389

EP - 399

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 3

ER -